Skip to main content

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Access & Citations

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

Online attention

Altmetric score 5
  • 8 tweeters
  • 1 Redditors
  • 17 Mendeley

This article is in the 70th percentile (ranked 129,161st) of the 434,491 tracked articles of a similar age in all journals and the 85th percentile (ranked 39th) of the 256 tracked articles of a similar age in BMC Cancer

View more on Altmetric

Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.